Abstract: Aspects of the disclosure relate to compositions and methods for eliciting (or enhancing) anti-repeat-associated non-ATG (RAN) protein antibody expression or production in a subject. Administration of the compositions according to the methods of the present disclosure may in some embodiments result in decreased levels of RAN protein expression and/or aggregation. Such compositions and methods may therefore be useful for the treatment of diseases and disorders known to be associated with RAN proteins.

Abstract: A series of PRMT5 inhibitor compounds are described. The compounds are useful as PRMT5 inhibitor compounds and in the treatment of PRMT5 mediated diseases, disorders, and symptoms thereof.

Abstract: A method is provided for identifying synthetic “deep-fake” audio samples versus organic audio samples. Methods may include: generating a model of a vocal tract using one or more organic audio samples from a user; identifying a set of bigram-feature pairs from the one or more audio samples; estimating the cross-sectional area of the vocal tract of the user when speaking the set of bigram-feature pairs; receiving a candidate audio sample; identifying bigram-feature pairs of the candidate audio sample that are in the set of bigram-feature pairs; calculating a cross-sectional area of a theoretical vocal tract of a user when speaking the identified bigram-feature pairs; and identifying the candidate audio sample as a deep-fake audio sample in response to the calculated cross-sectional area of the theoretical vocal tract of a user failing to correspond within a predetermined measure of the estimated cross sectional area of the vocal tract of the user.

Abstract: Provided herein are methods and compositions useful in the screening and production of recombinant AAV (rAAV) that have structural fitness and potency in insect cells and mammalian cells. The disclosure provides a directed evolution system for generating and selecting rAAV variants based on their Kozak sequences. In some embodiments, methods disclosed herein comprise the use of modified Kozak sequences to express AAV2 VP1 proteins in amounts that are useful for producing rAAV particles having high infectivities and/or transduction efficiencies. In some embodiments, methods of producing, and methods of screening, rAAV are provided that comprise the steps of infecting insect cells by administering rAAV to these cells, recovering rAAV-integrated DNA from these insect cells, and transfecting recovered rAAV into mammalian cells. Also provided herein are nucleic acids comprising nucleotide sequences encoding novel Kozak sequences.

Abstract: A tissue contact surface for use on a surgical retractor is provided. The tissue contact surface comprises a generally smooth surface; and a plurality of partial ellipsoid surfaces extending out and away from the generally smooth surface. The plurality of partial ellipsoid surfaces comprise a first partial ellipsoid surface and an adjacent second partial ellipsoid surface. The first partial ellipsoid surface extends approximately 0.5 millimeters to 1 centimeter out from the generally smooth surface. A spacing between the first partial ellipsoid surface and the second partial ellipsoid surface is approximately 0.5 millimeters to 1 centimeter. In various embodiments, the plurality of partial ellipsoid surfaces are 3D printed onto the generally smooth surface.

Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.

Abstract: An acoustic waveguide having high-Q resonator characteristics is disclosed and a fabrication method is described. Various waveguide-based test-vehicles, implemented in single crystal silicon and transduced by thin aluminum nitride films, are demonstrated. Silicon resonators with type-I and type-II dispersion characteristics are presented to experimentally justify the analytical mode synthesis technique for realization of high quality-factor silicon Lamb wave resonators. An analytical design procedure is also presented for geometrical engineering of the waveguides to realize high-Q resonators without the need for geometrical suspension through narrow tethers or rigid anchors. The effectiveness of the dispersion engineering methodology is verified through development of experimental test-vehicles in 20 ?m-thick single-crystal silicon (SCS) waveguides with 500 nm aluminum nitride transducers.

Abstract: The present disclosure provides AAV8 vectors and variants thereof that express nucleic acids sharing identity to a codon optimized NAGLU (coNAGLU) that improves transduction and distribution in brain cells and will improve disease outcomes in the Mucopolysaccharidoses IIIB (MPS IIIB) mouse model. The present disclosure also provides methods of treatment of a subject, and methods of transducing one or more brain cells, by administering these vectors, as well as uses of these vectors in the manufacture of medicaments for treatment. The present disclosure also provides compositions and host cells comprising rAAV vectors and rAAV particles that express a coNAGLU heterologous nucleic acid and confer enhanced transduction efficiency in human cells, such as brain cells (e.g., neurons). These compositions may be administered to a subject in need thereof.

Abstract: The disclosure provides methods of treating coronavirus infections (e.g., COVID-19) by administering hematopoietic stem cells, with or without an immune checkpoint inhibitor (e.g., PD-1 antagonist). The disclosure also provides methods of treating coronavirus infections (e.g., COVID-19) by adoptive cell transfer of polyclonal T cells and coronavirus-specific T cells (e.g., SARS-CoV-2-specific T cells).

Abstract: An adaptive filter includes, in part, a linear filter, and a non-linear resonator coupled to the linear filter and adapted to resonate at a frequency that is an integer multiple of the frequency of a received RF signal. The adaptive filter filters out the received RF signal. The resonant frequency may be twice the frequency of the received RF signal. The adaptive filter optionally includes a second non-linear resonator coupled to the linear filter and adapted to resonate at a frequency defined by a sum of the integer multiple of the frequency of the received signal and an offset frequency.

Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

Abstract: Disclosed are a system and methods for calibrating wall shear stress sensors. The system includes an oscillating plate coupled to an actuator and mounted on a rolling elements, and one or more sensors coupled to a height adjusting device. The system can further comprise a height control rod coupled to a height control base and a sensor holder configured to house the one or more sensors and supported on a connector, the connector configured to be rotatably disposed about the height control rod. The system can be calibrated by causing the actuator to oscillate the oscillating plate at a frequency, sensing, using the one or more sensors, shear stress at a wall, the shear stress at the wall being associated with a velocity field, and determining a theoretical wall shear stress based on fluid properties, the frequency, and the height of the one or more sensors above the oscillating plate.

Abstract: Methods and systems are directed to creating a physical unclonable function (PUF) on a Field Programmable Gate Array (FPGA) and generating a unique signature for a device. The method includes, in part, designing a PUF by taking advantages of programmable logic elements on the FPGA, and extracting uninitialized values associated with one or more storage elements comprised in the PUF when the FPGA is powered up. The extracted uninitialized values can be combined to generate the unique signature for the device. The one or more storage elements can be bi-stable memory cells that are mapped to look up tables (LUTs) on the FPGA. The coordinates of these LUTs can be determined based on hamming distance analysis. Alternatively, the one or more storage elements can be memory cells associated with boundary scan cells of a boundary scan chain.

Abstract: The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout.

Abstract: Various examples are provided related to automated security analysis of baseband firmware. In one example, a system includes a wireless front end and processing circuitry communicatively coupled to the wireless front end and a target device. The processing circuitry can generate mutated packets based upon a device state of the target device; provide the mutated packets for transmission to the target device; receive feedback information from the target device in response to reception of the mutated packets; and identify a firmware flaw associated with the target device in response to the feedback information. In another example, a method includes generating mutated packets based upon a device state of a target device; transmitting the mutated packets to the target device; receiving feedback information from the target device in response to reception of the mutated packets; and identifying a firmware flaw associated with the target device using the feedback information.

Abstract: Methods of producing colored and superhydrophobic surfaces, objects, and coatings using a colored paint that imparts a superhydrophobic surface on an object is a suspension of hydrophobic particles in a polymeric binder and a plasticizer in a solvent or mixed solvent, wherein at least a portion of the hydrophobic particles are colored particles. Colored particles can be ultramarine, iron oxide, chromium oxide, or any other colored metal oxide. The hydrophobic particles can be metal oxide particles that are surface functionalized with a fluorinated alkyl silane or an alkyl silane. The binder is a mixture of PDVF and PMMA in a ratio of 3:1 to 10:1. The plasticizer is a mixture of triethyl phosphate and perfluoro(butyltetrahydrofuran) or other perfluorinated hydrocarbon. Surfaces coated using this paint display contact angles in excess of 150° and resist abrasion.

Abstract: A method, apparatus, and computer program product are provided for identifying individuals using electronic fingerprint data, providing residence mapping functionality, resolving conflicts relating to the update of electronic records, and optimizing performance relating to the access of electronic records.

Abstract: A particle portal imaging (PPI) system and method are provided that can be used to provide a “beam's eye view” of a patient's anatomy as a charged particle beam is delivered to a target region of the patient's body. The PPI system is capable of performing real-time image acquisition and in-situ dose monitoring using at least exit neutrons generated within the patient. The PPI system can perform charged particle treatment (PT) monitoring to monitor the particle beam being used for PT.

Abstract: The present disclosure includes genetically engineered, non-pathogenic Streptomyces bacterium with exogenous, non-native Thaxtomin A (ThxA) biosynthetic gene clusters conferring the genetically engineered, non-pathogenic Streptomyces bacterium with the ability to produce thaxtomin A. Also included are methods of providing thaxtomin producing capability in non-native Streptomyces bacterial strains, methods of producing thaxtomin compounds with the genetically engineered Streptomyces bacteria of the present disclosure, and methods of producing thaxtomin compounds and nitro-tryptophan analogs, and fluorinated thaxtomin compounds, analogs, and intermediates with the genetically engineered Streptomyces bacteria of the present disclosure.

Abstract: Embodiments of the present disclosure provide methods, systems, apparatus, and computer program products are for detecting whether a suspect component such as an integrated circuit (IC) or a system-on-chip (SoC) is recycled. Specifically, various embodiments involve processing power supply rejection ratio (PSRR) data obtained from a low drop-out regulator (LDO) used for the suspect component using a recycle detection machine learning model to generate a recycle prediction. In particular embodiments, the recycle detection machine learning model is developed based at least in part on degradation of PSRRs of LDOs. Accordingly, a determination is made as to whether the suspect component is recycled based on the recycle prediction. If so, then an indication that the suspect component is recycled is provided.